We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 317

Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity
  • Foley & Lardner LLP
  • USA
  • February 2 2016

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious


Australian Patent Office Provides Patent Eligibility Guidance
  • Foley & Lardner LLP
  • Australia, USA
  • December 17 2015

The Australian Patent Office (IP Australia) has issued final patent eligibility guidance under the Australian High Court's decision in D'Arcy v


Asset Transferee Cannot Appeal Reexamination
  • Foley & Lardner LLP
  • USA
  • February 4 2016

The Federal Circuit dismissed the appeal in Agilent Technologies, Inc. v. Waters Technologies Corp., because the appellant was not a “third-party


PTAB Trial Standard Of Review Requires Affirmance Despite Contrary Evidence
  • Foley & Lardner LLP
  • USA
  • January 14 2016

In Merck & Cie v. Gnosis S.p.A., the Federal Circuit affirmed the decision of the USPTO Patent Trial and Appeal Board (PTAB) that held the challenged


Incomplete Restriction Requirement Stops Clock For Patent Term Adjustment
  • Foley & Lardner LLP
  • USA
  • January 26 2016

In Pfizer v. Lee, the Federal Circuit affirmed the decision of the U.S. District Court for the Eastern District of Virginia that upheld the USPTO's


Federal Circuit interprets two important infringement provisions
  • Foley & Lardner LLP
  • USA
  • November 19 2015

In a single decision issued for companion cases Momenta Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA Inc. and Momenta Pharmaceuticals, Inc. v


Federal Circuit finds hole in “this” priority claim
  • Foley & Lardner LLP
  • USA
  • January 29 2014

In Medtronic CoreValve, LLC v. Edwards Lifesciences Corp., the Federal Circuit affirmed the district court's finding that the patent at issue was


Myriad sues Ambry for offering BRCA1BRCA2 breast cancer genetic testing
  • Foley & Lardner LLP
  • USA
  • July 11 2013

On July 9, 2013, Myriad Genetics, Inc. brought suit against Ambry Genetics Corporation, alleging that Ambry is infringing ten (10) patents by


Biosimilars can sit out patent dance, but may have to wait out second exclusivity period
  • Foley & Lardner LLP
  • USA
  • July 24 2015

In Amgen v. Sandoz, Fed. Cir., No. 15-1499 (July 21, 2015), a divided panel of the Federal Circuit issued its first decision interpreting the


Biosimilar pre-marketing notice always required
  • Foley & Lardner LLP
  • USA
  • December 15 2015

Judge Cohn of the U.S. District Court for the Southern District of Florida has issued another decision interpreting the complicated provisions of the